Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel treatments for metabolic dysfunction‑associated steatohepatitis (MASH), formerly known as NASH.
It is the developer of the first FDA‑approved therapy for adults with moderate to advanced liver fibrosis.
Address: 200 Barr Harbor Drive, Suite 200, West Conshohocken, PA 19428
Phone: (267) 327‑4445
-
Madrigal’s Rezdiffra Nears Blockbuster Status With $958M in First Full Year on Market
In its first full year on the market, West Conshohocken-based Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly got to blockbuster status, bringing in $958.4 million in…
-
Madrigal Pharmaceuticals Expands As Breakthrough Drug Fuels Growth
West Conshohocken’s Madrigal Pharmaceuticals is relocating its headquarters to accommodate rapid expansion, reports John George for The Philadelphia Business Journal. The creator of the first…
-
West Conshohocken’s Madrigal Pharmaceuticals Gets FDA Green Light
West Conshohocken’s Madrigal Pharmaceuticals earned a major win with the FDA approval of its first commercial product, reports John George for the Philadelphia Business Journal.…
Founding Partners
Advertisement
Affiliate Partners
